Therefore, we performed this meta-analysis systematically utilizing data from the published literature to evaluate the efficacy and safety of anti-PD-1/PD-L1 antibodies versus docetaxel in previously treated advanced NSCLC patients. The gene discussed is CD274; the disease is non-small cell lung carcinoma.